Last updated on February 2017

AdreView™ Myocardial Imaging for Risk Evaluation - A Multicentre Trial to Guide ICD Implantation in NYHA Class II & III Heart Failure Patients With 30%=LVEF=35%


Brief description of study

AdreView™ Myocardial Imaging for Risk Evaluation - A Multicentre Trial to Guide ICD Implantation in NYHA Class II & III Heart Failure Patients With 30%=LVEF=35%

Detailed Study Description

This is an event-driven Phase IIIb, multicentre, randomised, clinical study to demonstrate the efficacy of AdreView™ imaging for appropriately guiding the decision of implantable cardioverter defibrillator (ICD) implantation, in New York Health Association (NYHA) class II and III heart failure patients with 30%=left ventricular ejection fraction (LVEF)=35%%, and in particular, for identifying patients who are at low risk for sudden cardiac death and who would not benefit, or may suffer harm, from implantation of an ICD device.

Clinical Study Identifier: TX147491

Contact Investigators or Research Sites near you

Start Over

Mirza Muratovic

University of South Florida - USF Florida Cardiovascular Institute
Tampa, FL USA
  Connect »